ALKS Q2 2022 Earnings — Alkermes plc Revenue & Financial Results | Market Cap Arena

ALKSAlkermes plc

$5B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$276M-9.1% YoY

Gross Profit

$218M78.9% margin

Operating Income

-$34M-12.5% margin

Net Income

-$30M-10.9% margin

EPS (Diluted)

$-0.18

QoQ Revenue Growth

-0.8%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$12M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$2.0B

Total Liabilities

$875M

Stockholders' Equity

$1.1B

Cash & Equivalents

$255M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$276M	$304M	-9.1%
Gross Profit	$218M	$251M	-13.1%
Operating Income	-$34M	$4M	-879.4%
Net Income	-$30M	$2M	-1374.8%

Revenue Segments

Product

$191M50%

Vivitrol

$96M25%

Aristada And Aristada Initio

$75M20%

L Y B A L V I

$20M5%